Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Int AIDS Soc ; 22 Suppl 1: e25249, 2019 03.
Article in English | MEDLINE | ID: mdl-30907517

ABSTRACT

INTRODUCTION: HIV self-testing (HIVST) was first proposed as an additional option to standard HIV testing services in the 1980s. By 2015, two years after the first HIVST kit was approved for the American market and the year in which Unitaid invested in the "HIV Self-Testing AfRica (STAR) Initiative," HIVST remained unexplored with negligible access in low- and middle-income countries (LMIC). However, rapid progress had been made. This commentary outlines the interlinked market, regulatory and policy barriers that had inhibited product development and kept HIVST out of LMIC policy. We detail the components of STAR that enabled rapid HIVST scale-up, including critical investments in implementation, research, market forecasting, and engagement with manufacturers and regulators. DISCUSSION: The STAR Initiative has generated crucial information about how to distribute HIVST products effectively, ethically and efficiently. Service delivery models range from clinic-based distribution to workplace and partner-delivered approaches to reach first-time male testers, to community outreach to sex workers and general population "hotspots." These data directly informed supportive policy, notably the 2016 WHO guidelines strongly recommending HIVST as an additional testing approach, and regulatory change through support for WHO prequalification of the first HIVST kit in 2017. In July 2015, only two countries had national HIVST policies and were implementing HIVST. Three years later, 59 countries have policies, actively implemented in 28, with an additional 53 countries reporting policies under development. By end-November 2018 several quality-assured HIVST products had been registered, including two WHO prequalified tests. STAR Initiative countries have drafted regulations governing in vitro diagnostics, including HIVST products. With enabling policies, pre-qualification and regulations in place, donor procurement of kits has increased rapidly, to a forecasted estimate of 16 million HIVST kits procured by 2020. CONCLUSIONS: The STAR Initiative provided a strong foundation to introduce HIVST in LMICs and allow for rapid scale-up based on the wealth of multi-country evidence gathered. Together with sustained coordination and acceleration of market development work, HIVST can help address the testing gap and provide a focused and cost-effective means to expand access to treatment and prevention services.


Subject(s)
Global Health , HIV Infections/epidemiology , Mass Screening/methods , Reagent Kits, Diagnostic , Adult , Africa/epidemiology , Cost-Benefit Analysis , HIV Infections/prevention & control , Humans , Male , Mass Screening/economics , Serologic Tests
2.
BMJ ; 334(7590): 403, 2007 Feb 24.
Article in English | MEDLINE | ID: mdl-17259188

ABSTRACT

OBJECTIVE: To compare rapid diagnostic tests (RDTs) for malaria with routine microscopy in guiding treatment decisions for febrile patients. DESIGN: Randomised trial. SETTING: Outpatient departments in northeast Tanzania at varying levels of malaria transmission. PARTICIPANTS: 2416 patients for whom a malaria test was requested. INTERVENTION: Staff received training on rapid diagnostic tests; patients sent for malaria tests were randomised to rapid diagnostic test or routine microscopy MAIN OUTCOME MEASURE: Proportion of patients with a negative test prescribed an antimalarial drug. RESULTS: Of 7589 outpatient consultations, 2425 (32%) had a malaria test requested. Of 1204 patients randomised to microscopy, 1030 (86%) tested negative for malaria; 523 (51%) of these were treated with an antimalarial drug. Of 1193 patients randomised to rapid diagnostic test, 1005 (84%) tested negative; 540 (54%) of these were treated for malaria (odds ratio 1.13, 95% confidence interval 0.95 to 1.34; P=0.18). Children aged under 5 with negative rapid diagnostic tests were more likely to be prescribed an antimalarial drug than were those with negative slides (P=0.003). Patients with a negative test by any method were more likely to be prescribed an antibiotic (odds ratio 6.42, 4.72 to 8.75; P<0.001). More than 90% of prescriptions for antimalarial drugs in low-moderate transmission settings were for patients for whom a test requested by a clinician was negative for malaria. CONCLUSIONS: Although many cases of malaria are missed outside the formal sector, within it malaria is massively over-diagnosed. This threatens the sustainability of deployment of artemisinin combination treatment, and treatable bacterial diseases are likely to be missed. Use of rapid diagnostic tests, with basic training for clinical staff, did not in itself lead to any reduction in over-treatment for malaria. Interventions to improve clinicians' management of febrile illness are essential but will not be easy. TRIAL REGISTRATION: Clinical trials NCT00146796 [ClinicalTrials.gov].


Subject(s)
Fever/parasitology , Malaria, Falciparum/diagnosis , Microscopy/standards , Parasitology/standards , Reagent Strips/standards , Anti-Bacterial Agents/therapeutic use , Antimalarials/therapeutic use , Child , Female , Humans , Malaria, Falciparum/drug therapy , Male , Point-of-Care Systems/standards , Tanzania
3.
Malar J ; 5: 4, 2006 Jan 20.
Article in English | MEDLINE | ID: mdl-16423307

ABSTRACT

BACKGROUND: There is a need for improved targeting of antimalarial treatment if artemisinin combination therapy is to be successfully introduced in Africa. This study aimed to explore why malaria slides are requested and how their results guide treatment decisions in an area of low transmission of P. falciparum. METHODS: Outpatients attending a district hospital in a highland area of Tanzania were studied over a 3-week period. Clinical and social data were collected from patients who had been prescribed an antimalarial or sent for a malaria slide. Hospital slides were re-read later by research methods. RESULTS: Of 1,273 consultations 132(10%) were treated presumptively for malaria and 214(17%) were sent for a malaria slide; only 13(6%) of these were reported positive for P. falciparum but 96(48%) of the 201 slide-negative cases were treated for malaria anyway. In a logistic regression model, adults (OR 3.86, P < 0.01), a history of fever (OR1.72, P = 0.03) and a longer travel time to the clinic (OR 1.77 per hour travelled, P < 0.01) independently predicted the request for a malaria slide. Only a history of a cough predicted (negatively) the prescription of an antimalarial with a negative slide result (OR 0.44, P < 0.01). The sensitivity and specificity of hospital slide results were 50% and 96% respectively. CONCLUSION: Progress in targeting of antimalarials in low malaria transmission settings is likely to depend on consistent use of malaria microscopy and on the willingness of health workers to be guided by negative slide results. Further studies are needed to identify how this can be achieved.


Subject(s)
Antimalarials/therapeutic use , Malaria, Falciparum/diagnosis , Malaria, Falciparum/drug therapy , Microscopy/statistics & numerical data , Plasmodium falciparum/isolation & purification , Adolescent , Animals , Child, Preschool , Clinical Protocols/standards , Decision Making , Female , Humans , Logistic Models , Malaria, Falciparum/transmission , Male , Microscopy/methods , Sensitivity and Specificity , Tanzania
4.
BMJ ; 329(7476): 1212, 2004 Nov 20.
Article in English | MEDLINE | ID: mdl-15542534

ABSTRACT

OBJECTIVE: To study the diagnosis and outcomes in people admitted to hospital with a diagnosis of severe malaria in areas with differing intensities of malaria transmission. DESIGN: Prospective observational study of children and adults over the course a year. SETTING: 10 hospitals in north east Tanzania. PARTICIPANTS: 17,313 patients were admitted to hospital; of these 4474 (2851 children aged under 5 years) fulfilled criteria for severe disease. MAIN OUTCOME MEASURE: Details of the treatment given and outcome. Altitudes of residence (a proxy for transmission intensity) measured with a global positioning system. RESULTS: Blood film microscopy showed that 2062 (46.1%) of people treated for malaria had Plasmodium falciparum (slide positive). The proportion of slide positive cases fell with increasing age and increasing altitude of residence. Among 1086 patients aged > or = 5 years who lived above 600 metres, only 338 (31.1%) were slide positive, while in children < 5 years living in areas of intense transmission (< 600 metres) most (958/1392, 68.8%) were slide positive. Among 2375 people who were slide negative, 1571 (66.1%) were not treated with antibiotics and of those, 120 (7.6%) died. The case fatality in slide negative patients was higher (292/2412, 12.1%) than for slide positive patients (142/2062, 6.9%) (P < 0.001). Respiratory distress and altered consciousness were the strongest predictors of mortality in slide positive and slide negative patients and in adults as well as children. CONCLUSIONS: In Tanzania, malaria is commonly overdiagnosed in people presenting with severe febrile illness, especially in those living in areas with low to moderate transmission and in adults. This is associated with a failure to treat alternative causes of severe infection. Diagnosis needs to be improved and syndromic treatment considered. Routine hospital data may overestimate mortality from malaria by over twofold.


Subject(s)
Diagnostic Errors , Fever/etiology , Malaria, Falciparum/diagnosis , Adolescent , Adult , Aged , Child , Child, Preschool , Humans , Infant , Infant, Newborn , Malaria, Falciparum/mortality , Middle Aged , Prospective Studies , Regression Analysis , Tanzania/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...